Evaluation of axitinib to downstage <scp>cT</scp> 2a renal tumours and allow partial nephrectomy: a phase II study

Abstract

Neoadjuvant axitinib in cT2 ccRCC is feasible and, even with a modest decrease in size, allowed a tumour shrinkage <7 cm in 12 cases; however, PN procedures remained complex, requiring surgical expertise with possible morbidity.